Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...
Nearly 30 years after it first hit theaters, Paul W.S. Anderson's Event Horizon is finally getting a prequel. IDW Publishing has revealed Event Horizon: Dark Descent, a five-issue comic book series ...
The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...
Language-based agentic systems represent a breakthrough in artificial intelligence, allowing for the automation of tasks such as question-answering, programming, and advanced problem-solving. These ...
Currently the fixed-form tokenizer (recursive descent parser) is hand-written, and has bugs. It should be possible to generate the full fixed-form tokenizer from a grammar, that would contain specific ...
Abstract: This study presents a novel method for finding and evaluating mathematical expressions using Abstract Syntax Trees (AST). The approach is particularly adaptable for both academic and ...
Salt Lake City-based Recursion Pharmaceuticals is joining forces with the United Kingdom’s Exscientia, a biotechnology company that specializes in cancer research, in a $688 million deal executives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results